Company intelligence / Profile preview
CSL Limited
- Ownership
- Public · CSL
- Employees
- ~32000
- Development stage
- Commercial
Overview
CSL is a global leader in biotherapeutics with over a century of history. It has more than 580 clinical trials conducted or ongoing worldwide. Recent clinical milestones include regulatory approvals for new therapies such as garadacimab for hereditary angioedema in Switzerland and the sa-mRNA COVID vaccine Kostaive in Japan. The company maintains strong commercial performance with $22+ billion revenue in FY2024.
- Therapeutic areas
- Infectious DiseasesImmunologyNephrologyHematology
- Modalities
- Plasma-derived therapiesRecombinant proteinsVaccines (egg-based, cell-based, mRNA, adjuvanted)Gene therapyCell therapy
- Industry
- Pharma
Drug pipeline
37 assets36 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on CSL Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL Limited.